Morphic Holding, Inc. (MORF): Price and Financial Metrics

Morphic Holding, Inc. (MORF): $30.32

0.32 (+1.07%)

POWR Rating

Component Grades

Momentum

C

Stability

D

Sentiment

Quality

D

Add MORF to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#348 of 361

in industry

MORF Price/Volume Stats

Current price $30.32 52-week high $63.08
Prev. close $30.00 52-week low $19.34
Day low $29.78 Volume 273,300
Day high $30.60 Avg. volume 510,011
50-day MA $35.11 Dividend yield N/A
200-day MA $36.76 Market Cap 1.52B

MORF Stock Price Chart Interactive Chart >


Morphic Holding, Inc. (MORF) Company Bio


Morphic Holding, Inc. operates as a biopharmaceutical company, which engages in the research and development of oral small-molecule integrin therapeutics. It operates a Morphic integrin technology platform, MInT platform, to create a broad pipeline of programs across a variety of therapeutic areas. The company was founded by Timothy A. Springer in August 2014 and is headquartered in Waltham, MA.


MORF Latest News Stream


Event/Time News Detail
Loading, please wait...

MORF Latest Social Stream


Loading social stream, please wait...

View Full MORF Social Stream

Latest MORF News From Around the Web

Below are the latest news stories about MORPHIC HOLDING INC that investors may wish to consider to help them evaluate MORF as an investment opportunity.

Does Morphic Holding, Inc. (MORF) Have the Potential to Rally 92.88% as Wall Street Analysts Expect?

The average of price targets set by Wall Street analysts indicates a potential upside of 92.9% in Morphic Holding, Inc. (MORF). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Yahoo | December 20, 2023

Wall Street Analysts See a 150.17% Upside in Morphic Holding, Inc. (MORF): Can the Stock Really Move This High?

The mean of analysts' price targets for Morphic Holding, Inc. (MORF) points to a 150.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Yahoo | December 1, 2023

We're Not Very Worried About Morphic Holding's (NASDAQ:MORF) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Yahoo | November 23, 2023

Wall Street Analysts Think Morphic Holding, Inc. (MORF) Could Surge 160.84%: Read This Before Placing a Bet

The consensus price target hints at a 160.8% upside potential for Morphic Holding, Inc. (MORF). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Yahoo | November 15, 2023

Morphic to Present at November Investor Conferences

WALTHAM, Mass., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that its management team will participate in the upcoming Jefferies London Healthcare Conference and Evercore ISI HealthCONx Conference. Jefferies London Healthcare Conference Fireside Chat Date: Tuesday, November 14, 2023Time: 5:00 PM GMT/12:00 PM ETA live webcast of

Yahoo | November 10, 2023

Read More 'MORF' Stories Here

MORF Price Returns

1-mo -12.37%
3-mo 9.10%
6-mo 40.18%
1-year -16.77%
3-year -47.42%
5-year N/A
YTD 4.99%
2023 7.96%
2022 -43.54%
2021 41.22%
2020 95.51%
2019 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!